Nanohale AG (ETR:FYB)

BRIEF

published on 09/27/2024 at 09:05, 1 year 9 months ago

European Commission Approves Formycon and Fresenius Kabi's Biosimilar FYB202/Otulfi®

European Commission Formycon Fresenius Kabi FYB202 Ustekinumab
PRESS RELEASE

published on 09/27/2024 at 09:00, 1 year 9 months ago

Formycon and Fresenius Kabi receive European Commission approval for FYB202/Otulfi® (ustekinumab) for the treatment of serious inflammatory diseases
Formycon and Fresenius Kabi secure European Commission approval for FYB202/Otulfi® (ustekinumab) to treat inflammatory diseases, expanding biosimilar portfolio

Biosimilar Formycon Fresenius Kabi Ustekinumab European Commission Approval
BRIEF

published on 09/17/2024 at 06:55, 1 year 10 months ago

Formycon to Present FYB202 Biosimilar Data at EADV Congress and UEG Week

Clinical Data Biosimilar Formycon FYB202 Ustekinumab
PRESS RELEASE

published on 09/17/2024 at 06:50, 1 year 10 months ago

Formycon will present clinical data on its ustekinumab biosimilar candidate FYB202 at the EADV Congress in Amsterdam and the UEG Week in Vienna
Formycon to present clinical data on ustekinumab biosimilar FYB202 at EADV Congress in Amsterdam and UEG Week in Vienna. Biosimilar for psoriasis and IBD in final approval phase

Clinical Data Biosimilar Formycon Ustekinumab Approval Process
BRIEF

published on 08/19/2024 at 14:16, 1 year 11 months ago

First Berlin Equity Research Maintains Buy Rating for Formycon AG

BUY Rating Biosimilars Formycon Revenue Update H1/24 Results
PRESS RELEASE

published on 08/19/2024 at 14:11, 1 year 11 months ago

Original-Research: Formycon AG (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research updates Formycon AG (ISIN: DE000A1EWVY8) with H1/24 results, maintaining BUY rating and EUR 80 target price. Formycon raises FY/24 guidance due to stronger than expected results

First Berlin Equity Research BUY Rating Formycon AG H1/24 Results EUR 80 Target Price
BRIEF

published on 08/13/2024 at 06:55, 1 year 11 months ago

Formycon Reports Robust First Half-Year with Significant Milestones

Financial Results Biosimilars Clinical Milestones Formycon FYB201
PRESS RELEASE

published on 08/13/2024 at 06:50, 1 year 11 months ago

Formycon reports a strong first half-year with multiple milestones achieved
Formycon AG reports successful first half-year with key operational, clinical, and regulatory milestones achieved. Group revenue and EBITDA in line with expectations. Invitation to conference call today

Conference Call Revenue Formycon AG Milestones First Half-Year
BRIEF

published on 08/07/2024 at 06:55, 1 year 11 months ago

Formycon Announces Conference Call on 2024 Half-Year Results and Investor Conference Participation

Conference Call Investor Conferences Formycon AG Half-year Results Financial Outlook
PRESS RELEASE

published on 08/07/2024 at 06:50, 1 year 11 months ago

Formycon invites to conference call on 2024 half-year results and announces participation in international investor conferences
Formycon schedules conference call on 2024 half-year results and confirms participation in investor conferences. Details on webcast and management presentations

Financial Results Conference Call Investor Conferences Biosimilars Formycon

Published on 07/25/2026 at 00:35, 1 day 9 hours ago

Pathfinder Ventures Inc. Provides Corporate Update
Published on 07/24/2026 at 23:00, 1 day 11 hours ago

NV Gold Announces Closing of Non-Brokered Private Placement
Published on 07/24/2026 at 22:15, 1 day 11 hours ago

Gold Terra Announces Closing of First Tranche of C$10.8M LIFE Offering With Strong Participation From Strategic Shareholder David Harquail
Published on 07/24/2026 at 22:05, 1 day 12 hours ago

Findev Inc. Announces CCAA Proceedings Involving 1682 Victoria Park Avenue Inc. and Related Party Subordination Arrangement
Published on 07/24/2026 at 20:00, 1 day 14 hours ago

Unusual Machines to Announce Second Quarter 2026 Financial Results and Provide Corporate Update

View all ACCESSWIRE

Published on 07/24/2026 at 19:06, 1 day 15 hours ago

End of Stabilisation Notice
Published on 07/24/2026 at 19:04, 1 day 15 hours ago

Stabilisation Notice
Published on 07/24/2026 at 18:44, 1 day 15 hours ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 07/24/2026 at 17:50, 1 day 16 hours ago

Fuller, Smith & Turner PLC: Director / PDMR Shareholding
Published on 07/24/2026 at 17:40, 1 day 16 hours ago

2CRSi SA: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital as of May 31, 2026.

View all EQS

Published on 07/24/2026 at 18:50, 1 day 15 hours ago

Disclosure of transactions in own shares from July 20 to July 24, 2026
Published on 07/24/2026 at 18:11, 1 day 15 hours ago

H1 2026 liquidity contract statement for TF1
Published on 07/24/2026 at 18:06, 1 day 16 hours ago

TF1 First-Half 2026 Financial Report
Published on 07/24/2026 at 18:00, 1 day 16 hours ago

TF1 H1 2026 results - Press release
Published on 07/24/2026 at 08:00, 2 days 2 hours ago

Accor signs a definitive binding agreement on the sale of its stake in Essendi

View all LES ECHOS COMFI WIRE

News